Seroatlas · Human Serome Atlas

OXNAD1

Oxidoreductase NAD-binding domain-containing protein 1

Also known as: MGC15763, OXND1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96HP4
Gene: OXNAD1
Ensembl: ENSG00000154814
Chromosome: 3
Canonical length: 312 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm

OverviewNCBI Gene

Predicted to enable oxidoreductase activity. Located in mitochondrion. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

312 residues, UniProt reviewed canonical sequence.

>Q96HP4|OXNAD1
     1  MACAAVMIPG LLRCSVGAIR IEAASLRLTL STLRHLTLTS IMKSKRKTDH MERTASVLRR
    61  EIVSAAKVCG AASESPSVKS LRLLVADQDF SFKAGQWVDF FIPGVSVVGG FSICSSPRLL
   121  EQERVIELAV KYTNHPPALW VHNTCTLDCE VAVRVGGEFF FDPQPADASR NLVLIAGGVG
   181  INPLLSILRH AADLLREQAN KRNGYEIGTI KLFYSAKNTS ELLFKKNILD LVNEFPEKIA
   241  CSLHVTKQTT QINAELKPYI TEGRITEKEI RDHISKETLF YICGPPPMTD FFSKQLENNH
   301  VPKEHICFEK WW

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against OXNAD1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 17 nTPM

Expression across tissuesHPA

Tissue

thymus: 17 nTPM
lymph node: 16 nTPM
liver: 16 nTPM
skeletal muscle: 14 nTPM
small intestine: 13 nTPM
duodenum: 12 nTPM

Single-cell type

t-cells: 336 nCPM
nk-cells: 186 nCPM
innate lymphoid cells: 174 nCPM
choroid plexus epithelial cells: 153 nCPM
myonuclei: 143 nCPM
epicardial cells: 143 nCPM

Immune cell

naive CD4 T-cell: 81 nTPM
naive CD8 T-cell: 62 nTPM
memory CD4 T-cell: 35 nTPM
MAIT T-cell: 30 nTPM
memory CD8 T-cell: 25 nTPM
gdT-cell: 23 nTPM

Brain region

choroid plexus: 16 nTPM
cerebral cortex: 16 nTPM
white matter: 15 nTPM
basal ganglia: 15 nTPM
thalamus: 14 nTPM
pons: 14 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.46
gnomAD pLI: 0
gnomAD missense Z: -0.45
DepMap mean gene effect: 0.01
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

oxidoreductase activity

Cellular components

mitochondrion

Protein domainsUniProt · Pfam · InterPro

Oxidoreductase FAD/NAD(P)-binding
FAD-binding domain, ferredoxin reductase-type
Riboflavin synthase-like beta-barrel
Ferredoxin-NADP reductase (FNR), nucleotide-binding domain
Oxidoreductase NAD-binding domain
Oxidoreductase NAD-binding domain-containing protein

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads OXNAD1 as an antibody target. Whether an autoantibody or antibody against OXNAD1 could matter depends on whether native OXNAD1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

OXNAD1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label OXNAD1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...